On February 6, 2015, 2,475,000 shares of common stock were issued at a price of $3.75 per share. Net cash proceeds of $8.5million were received.

On February 13, 2015, 343,383 shares of common stock were issued at a price of $3.75 per share. Net cash proceeds of $1.2 million were received.

On February 20, 2015, The Company purchased the Nucleosomics® WO2005019826: Detection of Histone Modifications in Cell-Free Nucleosomes patent (i.e. the patent that underlies the NuQ®-M tests) from Chroma Therapeutics Limited for the sum of $55,000.

On February 23, 2015, 25,000 warrants were exercised at $2.20 per share, giving cash proceeds of $55,000. As a result a total of 25,000 shares of common stock were issued.

On February 27, 2015, the ratchet provision within 409,750 warrants expired and the associated derivative liability was cancelled on that date.

On March 6, 2015, 400,000 shares of common stock were issued at a price of $3.75 per share. Net cash proceeds of $1.4 million were received.